全身[18F]FDG PET/MR在癌症M分期中的诊断效能:系统评价与Meta分析
该诊断性Meta分析纳入52项研究、2289例患者和2072个转移灶,评估全身[18F]FDG PET/MR在[18F]FDG高摄取恶性肿瘤M分期中的诊断效能。患者水平汇总敏感度和特异度分别为0.95(95%CI: 0.91-0.97)和0.99(95%CI: 0.97-1.00),病灶水平分别为0.97(95%CI: 0.91-0.99)和0.97(95%CI: 0.90-0.99)。作者结论认为其在高摄取恶性肿瘤M分期中高度准确,但当前指南尚未将其列为常规影像技术。
要点
- 患者水平汇总敏感度0.95、特异度0.99,病灶水平分别为0.97和0.97。
- 亚组中乳腺癌和妇科肿瘤汇总敏感度分别为1.00和0.97,特异度分别为0.97和1.00。
- 作者指出当前指南未将[18F]FDG PET/MR列为常规影像技术。
核心结论
- 全身[18F]FDG PET/MR在已报道的[18F]FDG高摄取恶性肿瘤M分期中高度准确,各肿瘤类型均显示高敏感度和特异度。
研究设计与样本
- 诊断性Meta分析,纳入52项符合条件的研究,共2289例患者和2072个转移灶,参考标准为组织病理学、随访或非同步多模态影像,采用STATA 16进行分析。
诊断标准与关键数值
- 患者水平汇总敏感度0.95(95%CI: 0.91-0.97),汇总特异度0.99(95%CI: 0.97-1.00)。
- 病灶水平汇总敏感度0.97(95%CI: 0.91-0.99),汇总特异度0.97(95%CI: 0.90-0.99)。
- 肺癌汇总敏感度0.90、特异度1.00;胃肠道癌汇总敏感度0.93、特异度0.98;乳腺癌汇总敏感度1.00、特异度0.97;妇科肿瘤汇总敏感度0.97、特异度1.00。
- 非小细胞肺癌汇总敏感度0.92、特异度1.00;结直肠癌汇总敏感度0.96、特异度0.95;宫颈癌汇总敏感度0.86、特异度1.00。
临床应用与阅片要点
- 作者认为本研究结果可能有助于临床医生和患者对[18F]FDG PET/MR的临床性能建立信心。
- 作者指出[18F]FDG PET/MR因可及性和流程问题尚未被现行指南列为常规影像技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To calculate the pooled diagnostic performances of whole-body [18F]FDG PET/MR in M staging of [18F]FDG-avid cancer entities.
METHODS: A diagnostic meta-analysis was conducted on the [18F]FDG PET/MR in M staging, including studies: (1) evaluated [18F]FDG PET/MR in detecting distant metastasis; (2) compared[ 18F]FDG PET/MR with histopathology, follow-up, or asynchronous multimodality imaging as the reference standard; (3) provided data for the whole-body evaluation; (4) provided adequate data to calculate the meta-analytic performances. Pooled performances were calculated with their confidence interval. In addition, forest plots, SROC curves, and likelihood ratio scatterplots were drawn. All analyses were performed using STATA 16.
RESULTS: From 52 eligible studies, 2289 patients and 2072 metastases were entered in the meta-analysis. The whole-body pooled sensitivities were 0.95 (95%CI: 0.91-0.97) and 0.97 (95%CI: 0.91-0.99) at the patient and lesion levels, respectively. The pooled specificities were 0.99 (95%CI: 0.97-1.00) and 0.97 (95%CI: 0.90-0.99), respectively. Additionally, subgroup analyses were performed. The calculated pooled sensitivities for lung, gastrointestinal, breast, and gynecological cancers were 0.90, 0.93, 1.00, and 0.97, respectively. The pooled specificities were 1.00, 0.98, 0.97, and 1.00, respectively. Furthermore, the pooled sensitivities for non-small cell lung, colorectal, and cervical cancers were 0.92, 0.96, and 0.86, respectively. The pooled specificities were 1.00, 0.95, and 1.00, respectively.
CONCLUSION: [18F]FDG PET/MR was a highly accurate modality in M staging in the reported [18F]FDG-avid malignancies. The results showed high sensitivity and specificity in each reviewed malignancy type. Thus, our findings may help clinicians and patients to be confident about the performance of [18F]FDG PET/MR in the clinic.
CLINICAL RELEVANCE STATEMENT: Although [18F]FDG PET/MR is not a routine imaging technique in current guidelines, mostly due to its availability and logistic issues, our findings might add to the limited evidence regarding its performance, showing a sensitivity of 0.95 and specificity of 0.97.
KEY POINTS: • The whole-body [18F]FDG PET/MR showed high accuracy in detecting distant metastases at both patient and lesion levels. • The pooled sensitivities were 95% and 97% and pooled specificities were 99% and 97% at patient and lesion levels, respectively. • The results suggested that 18F-FDG PET/MR was a strong modality in the exclusion and confirmation of distant metastases.
引用
- Mirshahvalad SA, Kohan A, Metser U, et al. Diagnostic performance of whole-body [18F]FDG PET/MR in cancer M staging: A systematic review and meta-analysis. Eur Radiol. 2023. PMID: 37535156. doi:10.1007/s00330-023-10009-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。